Virios Therapeutics (NASDAQ:VIRI – Get Free Report) and Palatin Technologies (PINK:PTNT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
Risk & Volatility
Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Virios Therapeutics and Palatin Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Virios Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Palatin Technologies | 0 | 0 | 1 | 0 | 3.00 |
Profitability
This table compares Virios Therapeutics and Palatin Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Virios Therapeutics | N/A | -130.33% | -115.00% |
| Palatin Technologies | N/A | N/A | -365.57% |
Earnings & Valuation
This table compares Virios Therapeutics and Palatin Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Virios Therapeutics | N/A | N/A | -$5.30 million | ($0.27) | -15.41 |
| Palatin Technologies | $4.49 million | 32.44 | -$29.74 million | ($1.55) | -3.61 |
Virios Therapeutics has higher earnings, but lower revenue than Palatin Technologies. Virios Therapeutics is trading at a lower price-to-earnings ratio than Palatin Technologies, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Palatin Technologies shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Comparatively, 7.1% of Palatin Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Palatin Technologies beats Virios Therapeutics on 7 of the 12 factors compared between the two stocks.
About Virios Therapeutics
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
About Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
